Cisplatin-induced ototoxicity: Effects, mechanisms and protection strategies

Toxics

Volumn 3, Issue 3, 2015, Pages 268-293

  Callejo, Angela ^a   Sedó Cabezón, Lara ^b   Juan, Ivan Domènech ^a,c   Llorens, Jordi ^b,c  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cisplatin; Hearing loss; Intratympanic; Ototoxicity; Protective treatment

Indexed keywords

EID: 84962377131     PISSN: None     EISSN: 23056304     Source Type: Journal    
DOI: 10.3390/toxics3030268     Document Type: Review

References (174)

1. Rybak, L.P.; Whitworth, C.A.; Mukherjea, D.; Ramkumar, V. Mechansims of cisplatin-induced ototoxicity and prevention. Hear Res. 2007, 226, 157-167.
2. Rybak, L.P.; Mukherjea, D.; Jajoo, S.; Ramkumar, V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J. Exp. Med. 2009, 219, 177-186.
3. Hill, G.W.; Morest, D.K.; Parham, K. Cisplatin-Induced ototoxicity: Effect of intatympanic dexamethasone injections. Otol. Neurotol. 2008, 29, 1005-1011.
4. Wang, D.; Lippard, S.J.; Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4, 307-320.
5. Rybak, L. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr. Opin. Otolaryngol. Head Neck Surg. 2007, 15, 364-369.
6. Daldal, A.; Odabasi, O.; Serbetcioglu, B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol. Head Neck Surg. 2007, 137, 747-752.
7. Van den Berg, J.H.; Beijnen, J.H.; Balm, A.J.M.; Schellens, J.H.M. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat. Rev. 2006, 32, 390-397.
8. Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31, 1869-1883.
9. Gonzalez, V.M.; Fuertes, M.A.; Alonso, C.; Perez, J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol. Pharmacol. 2001, 59, 657-663.
10. Yang, Z.; Schumaker, L.M.; Egorin, M.J.; Zuhowski, E.G.; Guo, Z.; Cullen, K.J. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res. 2006 12, 5817-5825.
11. Brenner, C.; Grimm, S. The permeability transition pore complex in cancer cell death. Oncogene 2006, 25, 4744-4756.
12. Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Araujo, N.; Pinna, G.; Larochette, N.; Zamzami, N.; et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008, 27, 4221-4232.
13. Vaseva, A, V.; Marchenko, N.D.; Ji, K.; Tsirka, S.E.; Holzmann, S.; Moll, U.M. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012, 149, 1536-1548.
14. Holzer, A.K.; Samimi, G.; Katano, K.; Naerdemann, W.; Lin, X.; Safaei, R.; Howell, S.B. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 2004, 66, 817-823.
15. öhrvik, H.; Thiele, D.J. The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy. J. Trace Elem. Med. Biol. 2015, 31, 178-182.
16. Ciarimboli, G.; Deuster, D.; Knief, A.; Sperling, M.; Holtkamp, M.; Edemir, B.; Pavenstädt, H.; Lanvers-Kaminsky, C.; am Zehnhoff-Dinnesen, A.; Schinkel, A.H.; et al. Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010, 176, 1169-1180.
17. Lee, Y.Y.; Choi, C.H.; Do, I.G.; Song, S.Y.; Lee, W.; Park, H.S.; Song, T.J.; Kim, M.K.; Kim, T.J.; Lee, J.W.; et al. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol. Oncol. 2011, 122, 361-365.
18. Xu, X.; Duan, L.; Zhou, B.; Ma, R.; Zhou, H.; Liu, Z. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin. Exp. Pharmacol. Physiol. 2012, 39, 786-792.
19. Blair, B.G.; Larson, C.A.; Safaei, R.; Howell, S.B. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin. Cancer Res. 2009, 15, 4312-4321.
20. Van den Berghe, P.V.; Folmer, D.E.; Malingré, H.E.; van Beurden, E.; Klomp, A.E.; van de Sluis, B.; Merkx, M.; Berger, R.; Klomp, L.W. Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem. J. 2007, 407, 49-59.
21. Blair, B.G.; Larson, C.A.; Adams, P.L.; Abada, P.B.; Pesce, C.E.; Safaei, R.; Howell, S.B. Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol. Pharmacol. 2011, 79, 157-166.
22. Katano, K.; Safaei, R.; Samimi, G.; Holzer, A.; Rochdi, M.; Howell, S.B. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol. Pharmacol. 2003, 64, 466-473.
23. Komatsu, M.; Sumizawa, T.; Mutoh, M.; Chen, Z.S.; Terada, K.; Furukawa, T.; Yang, X.L.; Gao, H.; Miura, N.; Sugiyama, T.; et al. Cooper-Transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin reistance. Cancer Res. 2000, 60, 1312-1316.
24. Samimi, G.; Safaei, R.; Katano, K.; Holzer, A.K.; Rochdi, M.; Tomioka, M.; Goodman, M.; Howell, S.B. Increased expression of coppler efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 2004, 10, 4661-4669.
25. Kuo, M.T.; Chen, H.H.; Song, I.S.; Savaraj, N.; Ishikawa, T. The roles of cooper transporters in cisplatin resistance. Cancer Metastasis Rev. 2007, 26, 71-83.
26. Ciarimboli, G.; Ludwig, T.; Lang, D.; Pavenstädt, H.; Koepsell, H.; Piechota, H.J.; Haier, J.; Jaehde, U.; Zisowsky. J.; Schlatter, E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005, 167, 1477-1484.
27. Ciarimboli, G. Organic cation transporters. Xenobiotica. 2008, 38, 936-971.
28. Ciarimboli, G.; Schlatter, E. Regulation of organic cation transport. Pflugers. Arch. 2005, 449, 423-441.
29. Filipski, K.K.; Mathijssen, R.H.; Mikkelsen, T.S.; Schinkel, A.H.; Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 2009, 86, 396-402.
30. Lanvers-Kaminsky, C.; Sprowl, J.A.; Malath, I.; Deuster, D.; Eveslage, M.; Schlatter, E.; Mathijssen, R.H.; Boos, J.; Jürgens, H.; Am Zehnhoff-Dinnesen, A.G.; et al. Human OCT2 variant c.808G > T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 2015, 16, 323-332.
31. Nakamura, T.; Yonezawa, A.; Hashimoto, S.; Katsura, T.; Inui, K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 2010, 80, 1762-1767.
32. El-Khateeb, M.; Appleton, T.G.; Gahan, L.R.; Charles, B.G.; Berners-Price, S.J.; Bolton, A.M. Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques. J. Inorg. Biochem. 1999, 77, 13-21.
33. Eastman A. Cross-Linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem. Biol. Interact. 1987, 61, 241-248.
34. 2+, and the hydrolysis product of cisplatin in the rat. Cancer Chemother. Pharmacol. 1991, 29, 29-32.
35. Ekborn, A.; Lindberg, A.; Laurell, G. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother. Pharmacol. 2003, 51, 36-42.
36. Huang, Z.; Timerbaev, A.R.; Keppler, B.K.; Hirokawa, T. Determination of cisplatin and its hydrolytic metabolite in human serum by capillary electrophoresis techniques. J. Chromatogr. 2006, 1106, 75-79.
37. Watanabe, K.; Inai, S.; Jinnouchi, K. Expression of caspase-activated deioxyribonuclease (CAD) and caspase-3 (CPP32) in the cochlea of cisplatin (CPPD)-treated guinea pigs. Auris. Nasis. Larynx 2003, 30, 219-225.
38. Wang, J.; Ladrech, S.; Pujol, R. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res. 2004, 69, 217-224.
39. Previati, M.; Lanzoni, I.; Astolfi, L. Cisplatin cytotoxicity in organ of Corti derived immortalized cells. J. Cell. Biochem. 2007, 101, 1185-1197.
40. Mukherjea, D.; Whitworth, C.A.; Nandish, S. Expression of the kidney injury molecule 1 in the rat cochlea and induction by cisplatin. Neuroscience 2006, 139, 733-740.
41. So, H.; Kim, H.; Lee, J.H. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J. Assoc. Res. Otolaryngol. 2007, 8, 338-355.
42. Cleric, W.J.; DiMartino, D.L.; Prasad, M.R. Direct effects of reactive oxygen species on cochlear outer hair cell shape in vitro. Hear Res. 1995, 84, 30-40.
43. García-Berrocal, J.; Nevado, J.; Ramírez-Camacho, R.; Sanz, R.; González-García, J.A.; Sánchez-Rodríguez, C.; Cantos, B.; España, P.; Verdaguer, J.M.; Trinidad Cabezas, A. The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear. Br. J. Pharmacol. 2007, 152, 1012-1020.
44. Lee, J.E. Nakagawa, T.; Kita, T.; Kim, T.S.; Endo, T.; Shiga, A.; Iguchi, F.; Lee, S.H.; Ito, J. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta. Otolaryngol. 2004, 124, 1131-1135.
45. Ikeda, K.; Sunose, H.; Takasaka, T. Effects of free radicals on the intracellular calcium concentration in the isolated outer hair cell of the guinea pig cochlea. Acta. Otolrayngol. 1993, 113, 137-141.
46. Pigeolet, E.; Corbisier, P.; Houbion, A.; Lambert, D.; Michiels, C.; Raes, M.; Zachary, M.D.; Remacle, J. Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and oxygen derived free radicals. Mech. Ageing Dev. 1990, 51, 283-297.
47. Liang, F.; Schulte, B.A.; Qu, C.; Hu, W.; Shen, Z. Inhibition of the calcium-and voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. Neuroscience 2005, 135, 263-271.
48. Hughes, F.M., Jr.; Bortner, C.D.; Purdy, G.D.; Cidlowski, J.A. Intracellular K+ suppresses the activation of apoptosis in lymphocytes. J. Biol. Chem. 1997, 272, 30567-30576.
49. Bortner, C.D.; Cidlowski, J.A. A necessary role for cell shrinkage in apoptosis. Biochem. Pharmacol. 1998, 56, 1549-1559.
50. Watanabe, K.; Inai, S.; Jinnouchi, K.; Bada, S.; Hess, A.; Michel, O.; Yagi, T. Nuclear-Factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOS II) pathway damages the stria vascularis in cisplatin-treated mice. Anticancer Res. 2002, 22, 4081-4085.
51. Chung, W.H.; Boo, S.H.; Chung, M.K.; Lee, H.S.; Cho, Y.S.; Hong, S.H. Proapoptotic effects of NF-kappaB on cisplatin-induced cell death in auditory cell line. Acta Otolaryngol. 2008, 128, 1063-1070.
52. So, H.; Kim, Y.; Kim, E.; Pae, H.O.; Chung, H.T.; Kim, H.J.; Kwon, K.B.; Lee, K.M.; Lee, H.Y.; Moon, S.K.; et al. Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatroy cytokines via Nrf2/HO-1. J. Assoc. Res. Otolaryngol. 2008, 9, 290-306.
53. Dabholkar, M.; Christian, M.; Reed, E. Cisplatin. Cancer Chemother. Biol. Response Modif. 1994, 15, 87-98.
54. Ferry, K.V.; Hamilton, T.C.; Johnson, S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. 2000, 60, 1305-1313.
55. Selvakumaran, M.; Pisarcik, D.A.; Bao, R.; Yeung, A.T.; Hamilton, T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003, 63, 1311-1316.
56. De Laat, W.L.; Jaspers, N.G.; Hoeijmakers, J.H. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999, 13, 768-785.
57. Costa, R.M.; Chinganças, V.; Galhardo, S.; Carvalho, H.; Menck, C.F. The eukaryotic nucleotide excision repair pathway. Biochimie 2003, 85, 1083-1099.
58. Boonstra, A.; van Oudenaren, A.; Baert, M.; van Steeg, H.; Leenen, P.J.; van der Horst, G.T.; Hoeijmakers, J.H.; Salvelkoul, H.F.; Garssen, J. Differential ultraviolet-B-induced immunomodulation in XPA, XPC and CSB DNA repair-deficient mice. J. Invest. Dermatol. 2001, 117, 141-146.
59. Chen, Z.; Xu, X.S.; Yang, J.; Wang, G. Defining the function of XPC protein in psoralen and cisplatin-mediated DNA repair and mutagenesis. Carcinogenesis 2003, 24, 1111-1121.
60. Tornaletti, S.; Patrick, S.M.; Turchi, J.J.; Hanawalt, P.C. Behavior of T7 RNA polymerase and mammalian RNA-polymerase II at site-specific cisplatin adducts in the template DNA. J. Biol. Chem. 2003, 278, 35791-35797.
61. Guthrie, O.W.; Li-Korotky, H.S.; Durrant, J.D.; Balaban, C. Cisplatin induces cytoplasmic to nuclear translocation of nucleotide excision repair factors among spiral ganglion neurons. Hear Res. 2008, 239, 79-91.
62. Rybak, L.P.; Husain, K.; Morris, C.; Whitworth, C.; Somani, S. Effect of protective agents against cisplatin ototoxicity. Am. J. Otol. 2000, 21, 513-520.
63. Somani, S.M.; Husain, K.; Jagannathan, R.; Rybak, L.P. Ameriolation of cisplatin induced oto-and nephrotoxicity by protective agents. Ann. Neurosci. 2001, 8, 101-113.
64. Whitwort, C.A.; Ramkumar, V.; Jones, B.; Tsukasaki, N.; Rybak, L.P. Protection against cisplatin ototoxicity by adenosine agonists. Biochem. Pharmacol. 2004, 67, 1801-1807.
65. Cunningham, L.; Brandon, C.S. Heat shock inhibits both aminoglycoside-and cisplatin-induced sensory cell death. J. Assoc. Res. Otolaryngol. 2006, 7, 299-307.
66. Kim, H.J.; So, H.S.; Lee, J.H. Heme oxygenase-1 attenuates the cisplatin-induced apoptosis of auditory cells via down-regulation of reactive oxygen species generation. Free Radic. Biol. Med. 2006, 40, 1810-1819.
67. Kopke, R.D.; Liu, W.; Gabaizadeh, R. Use of organotypic cultures of Corti's organ to study the protective offects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am. J. Otol. 1997, 18, 559-571.
68. Cardinaal, R.M.; de Groot, J.C.; Huizing, E.H.; Veldman, J.E.; Smoorenburg, G.F. Cisplatin-induced ototoxicity: Morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs?. Hear Res. 2000, 144, 147-156.
69. Van Ruijven, M.W.; de Groot, J.C.; Smoorenburg, G.F. Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res. 2004, 197, 44-54.
70. Hinojosa, R.; Riggs, L.C.; Strauss, M.; Matz, G.J. Temporal bone histopathology of cisplatin ototoxicitiy. Am. J. Otol. 1995, 16, 731-740.
71. Smoorenburg, G.F.; de Groot, J.C.; Hamers, F.P.; Klis, S.F. Protection and spontaneous recovery from cisplatin-induced hearing loss. Ann. N. Y. Acad. Sci. 1999, 884, 192-210.
72. De Groot, J.C.; Hamers, F.; Gispen, W.; Smoorenburg, G. Co-Administration of the neurotrophic ACTH4-9 analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin. Hear Res. 1997, 106, 9-19.
73. Ress, B.D.; Sridhar, K.S.; Balkany, T.J.; Waxman, G.M.; Stagner, B.B.; Lonsbury-Martin, B.L. Effects of cis-platinum chemotherapy on otoacoustic emissions: The development of an objective screening protocol. Otolaryngol. Head Neck Surg. 1999, 121, 693-701.
74. Hatzopoulos, S.; DiStefano, M.; Campbell, K.C.M.; Falgione, D.; Ricci, D.; Rosignoli, M.; Finesso, M.; Albertin, A.; Previati, M.; Capitani, S.; et al. Cisplatin ototoxicity in the Sprague Dawley rat evaluated by distortion product otoacoustic emissions. Audiology 2001, 40, 253-264.
75. Freitas, M.R.; Silva, V.C.; Brito, G.A.; Carvalho Junior, J.V.; Gomes Junior, R.M.; Ribeiro Rde, A. Distortion-Product otoacoustic emissions and auditory brainstem responses sensitivity assessment in cisplatin-induced ototoxicity in rats. Braz. J. Otorhinolaryngol. 2009, 75, 476-484.
76. Bokemeyer, C.; Berger, C.C.; Hartmann, J.T. Analysis of risk factors for cisplatin induced ototoxicity in patients with testicular cancer. Br. J. Cancer 1998, 77, 1355-1362.
77. Kopelman, J.; Budnick, A.S.; Sessions, R.B.; Kramer, M.B.; Wong, G.Y. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancer and normal hearing. Laryngoscope 1988, 98, 858-864.
78. Zuur, C.L.; Simis, Y.J.W.; Lansdaal, P.E.M. Audiometric patterns in ototoxicity of intra-arterial cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol. Neurotol. 2006, 11, 318-330.
79. Fausti, S.A.; Larson, V.D.; Noffsinger, D.; Wilson, R.H.; Phillips, D.S.; Fowler, C.G. High-Frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear. 1994, 15, 232-239.
80. Knight, K.R.; Kraemer, D.F.; Winter, C.; Neuwelt, E.A. Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J. Clin. Oncol. 2007, 25, 1190-1195.
81. Osterhammel, D. High frequency audiometry. Clinical aspects. Scand. Audiol. 1980, 9, 249-256.
82. Biro, K.; Nozsek, L.; Prekopp, P. Characterisitics and risk factors of cisplatin induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology 2006, 70, 177-184.
83. Allen, G.C.; Tiu, C.; Koike, K.; Ritchey, A.K.; Kurs-Lasky, M.; Wax, M.K. Transient-Evoked otoacoustic emissions in children after cisplatin chemotherapy. Otolaryngol. Head Neck Surg. 1998, 118, 584-588.
84. Fausti, S.A.; Frey, R.H.; Henry, J.A.; Olson, D.J.; Schaffer, H.I. Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses. J. Am. Acad. Audiol. 1992, 3, 397-404.
85. Fausti, S.A.; Helt, W.J.; Phillips, D.S.; Gordon, J.S.; Bratt, G.W.; Sugiura, K.M.; Noffsinger, D. Early detection of ototoxicity using 1/6th-octave steps. J. Am. Acad. Audiol. 2003, 14, 444-450.
86. Buhrer, C.; Weinel, P.; Sauter, S. Acute onset deafness in a 4-year-old girl after a single infusion of cis-platinum. Pediatr. Hematol. Oncol. 1990, 7, 145-148.
87. Rademaker-Lakhai, J.M.; Crul, M.; Zuur, L. Relationship between cisplatin administration and the development of ototoxicity. J. Clin. Oncol. 2006, 24, 918-924.
88. Waters, G.S.; Ahmad, M.; Katsarkas, A.; Stanimir, G.; McKay, J. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: Influence of dosage and schedule of administration. Ear Hear. 1991, 12, 91-102.
89. Reddel, R.R.; Kefford, R.F.; Grant, J.M.; Coates, A.S.; Fox, R.M.; Tattersall, M.H. Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat. Rep. 1982, 66, 19-23.
90. McKeage, M. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995, 13, 228-244.
91. Coradini, P.P.; Cigana, L.; Selistre, S.G. Ototoxicity from cisplatin in childhood cáncer. Pediatr. Hematol. Oncol. 2007, 29, 355-360.
92. Li, Y.; Womer, R.B.; Silber, J.H. Predicting cisplatin ototoxicity in children: Influence of age and the cumulative dose. Eur. J. Cancer 2004, 40, 2445-2451.
93. Bertolini, P.; Lassalle, M.; Mercier, G.; Raquin, M.A.; Izzi, G.; Corradini, N.; Hartmann, O. Platinum compound-related ototoxicity in children: Long-Term follow-up reveals continuous worsening of hearing loss. J. Pediatr. Hematol. Oncol. 2004, 26, 649-655.
94. Kushner, B.H.; Budnick, A.; Kramer, K.; Modak, S.; Cheung, N.K. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006, 107, 417-422.
95. Knight, K.R.; Kraemer, D.F.; Neuwelt, E.A. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J. Clin. Oncol. 2005, 23, 8588-8596.
96. Gurney, J.G.; Tersak, J.M.; Ness, K.K.; Landier, W.; Matthay, K.K.; Schmidt, M.L.; Children's Oncology Group. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics 2007, 120, e1229-e1236.
97. Boothroyd, A. Developmental factors in speech recognition. Int. J. Audiol. 1970, 9, 30-38.
98. Davis, J.M.; Elfenbein, J.; Schum, R.; Bentler, R.A. Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J. Speech Hear. Disord. 1986, 51, 53-62.
99. Bess, F.H.; Dodd-Murphy, J.; Parker, R.A. Children with minimal sensorineural hearing loss: Prevalence, educational performance, and functional status. Ear Hear. 1998, 19, 339-354.
100. Horwitz, A.R.; Dubno, J.R.; Ahlstrom, J.B. Recognition of low-pass-filtered consonants in noise with normal and impaired high-frequency hearing. J. Acoust. Soc. Am. 2002, 111(1 Pt 1), 409-416.
101. Huang, E.; The, B.S.; Strother, D.R.; Davis, Q.G.; Chiu, K.J.; Lu, H.H.; Carpenter, L.S.; Mai, W.Y.; Chintagumpala, M.M.; South, M.; et al. Intensity-Modulated radiation therapy for pediatric medulloblastoma: Early report on the reduction of ototoxicity. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 599-605.
102. Chen, W.C.; Jackson, A.; Budnick, A. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006, 106, 820-829.
103. Hitchcock, Y.J.; Tward, J.D.; Szabo, A.; Bentz, B.G.; Shrieve, D.C. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 779-788.
104. Yancey, A.; Harris, M.S.; Egbelakin, A.; Gilbert, J.; Pisoni, D.B.; Renbarger, J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr. Blood Cancer 2012, 59, 144-148.
105. Huang, R.S.; Kistner, E.O.; Bleibel, W.K.; Shukla, S.J, Dolan, M.E. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol. Cancer Ther. 2007, 6, 31-36.
106. Peters, U.; Preisler-Adams, S.; Lanvers-Kaminsky, C. Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res. 2003, 23, 1249-1255.
107. Oldenburg, J.; Kraggerud, S.M.; Cvancarova, M; Lothe, R.A.; Fossa, S.D. Cisplatin-Induced long-term hearing impairment is associated with specific glutathione-s-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 2007, 25, 708-714.
108. Riedemann, L.; Lanvers, C.; Deuster, D. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics 2008, 8, 23-28.
109. Caronia, D.; Patino-Garcia, A.; Milne. R.L.; Zalacain-Diez, M.; Pita, G.; Alonso, M.R.; Moreno, L.T.; Sierrasesumaga-Ariznabarreta, L.; Benitez, J.; González-Neira, A. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009, 9, 347-353.
110. Rybak, L.P.; Kelly, T. Ototoxicity: Bioprotective mechanisms. Curr. Opin. Otolaryngol. Head Neck Surg. 2003, 11, 328-333.
111. Treskes, M.; Nijtmans, L.G.; Fichtinger-Schepman, A.M.; van der Vijgh, W.J. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem. Pharmacol. 1992, 43, 1013-1019.
112. Dickey, D.T.; Wu, Y.J.; Muldoon, L.L.; Neuwelt, E.A. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J. Pharmacol. Exp. Ther. 2005, 314, 1052-1058.
113. Lynch, E.D.; Gu, R.; Pierce, C.; Kil, J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res. 2005, 201, 81-89.
114. Wang, J.; Lloyd Faulconbridge, R.V.; Fetoni, A.; Guitton, M.J.; Pujol, R.; Pue, l J.L. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology 2003, 45, 380-393.
115. Choe, W.T.; Chinosornvatana, N.; Chang, K.W. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol. Neurotol. 2004, 25, 910-915.
116. Videhult, P.; Laurell, G.; Wallin, I.; Ehrsson, H. Kinetics of Cisplatin and its monohydrated complex with sulfur-containing compounds designed for local otoprotective administration. Exp. Biol. Med. 2006, 231, 1638-1645.
117. Goel, R.; Cleary, S.M.; Horton, C.; Kirmani, S.; Abramson, I.; Kelly, C.; Howell, S.B. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J. Natl. Cancer Inst. 1989, 81, 1552-1560.
118. Howell, S.B.; Taetle, R. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat. Rep. 1980, 64, 611-616.
119. Wimmer, C.; Mees, K.; Stumpf, P. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growht factor-2 in cisplatin-induced ototoxicity. Otol. Neurotol. 2004, 25, 33-40.
120. Hospers, G.A.; Eisenhauer, E.A.; de Vries, E.G. The sulthydryl containing compounds WR-2721 and glutathione as radio-and chemoprotective agents. A review, indications for use and prospects. Br. J. Cancer 1999, 80, 629-638.
121. Planting, A.S.; Catimel, G.; de Mulder, P.H. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann. Oncol. 1999, 10, 693-700.
122. Ekborn, A.; Hasson, J.; Ehrsson, H.; Eksborg, S.; Wallin, I.; Wagenius, G.; Laurell, G. High-Dose cisplatin with amifostine: Ototoxicity and pharmacokinetics. Laryngoscope 2004, 114, 1660-1667.
123. Campbell, K.C.; Meech, R.P.; Rybak, L.P.; Hughes, L.F. The effect of D-methionine on cochlear oxidative state with and without cisplatin administration: mechanisms of otoprotection. J. Am. Acad. Audiol. 2003, 14, 144-156.
124. Ekborn, A.; Laurell, G.; Johnstrom, P. D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics. Hear. Res. 2002, 165, 53-61.
125. Deegan, P.M.; Pratt, I.S.; Ryan, M.P. The nephrotoxicity, cytotoxicity and renal handling of cisplatin-methionine complex in male Wistar rats. Toxicology 1994, 98, 1-14.
126. Korver, K.D.; Rybak, L.P.; Whiworth, C.; Campbell, K.M. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol. Head Neck Surg. 2002, 126, 683-689.
127. Li, G.; Frenz, D.A.; Brahmblatt, S. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology 2001, 22, 163-176.
128. Kalcioglu, M.T.; Kilzilay, A.; Gulec, M. The protective effecto of erdosteine against ototoxicity induced by cisplatin in rats. Eur. Arch. Otorhinolaryngol. 2005, 262, 856-863.
129. Sun, J.; Liu, Y.; Kong, W.; Jiang, P.; Jiang, W. In vitro permeability of round window membrane to transforming dexamethasone with delivery vehicles-a dosage estimation. Chin. Med. J. 2007, 120, 2284-2289.
130. Parnes, L.S.; Sun, A.; Freeman, D.J. Corticosteroid Pharmacokinetics in the inner ear fluids: An animal study followed by clinical application. Laryngoscope 1999, 109S, 1-17.
131. Hamid, M.; Trune, D. Issues, indications, and controversies regarding intratympanic steroid perfusion. Curr. Opin. Otolaryngol. Head Neck Surg. 2008, 16, 434-440.
132. Lynch, E.D; Gu, R.; Pierce, C.; Kil, J. Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anticancer Drugs 2005, 16, 569-579.
133. Jeong, H.J.; Kim, S.J.; Moon, P.D. Antiapoptotic mechanism of cannabinoid receptor 2 agonist on cisplatin-induced apoptosis in the Hel-OC1 auditory cell line. J. Neurosci. Res. 2006, 85, 896-905.
134. Wu, Y.J.; Muldoon, L.L.; Neuwelt, E.A. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J. Pharmacol. Exp. Ther. 2005, 312, 424-431.
135. Minami, S.B.; Sha, S.H.; Schacht, J. Antioxidant protection in new animal model of cisplatin-induced ototoxicity. Hear. Res. 2004, 198, 137-143.
136. Hyppolito, M.A.; de Oliveira, J.A.; Rossato, M. Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur. Arch. Otorhinolaryngol. 2006, 263, 798-803.
137. Li, G.; Sha, S.H.; Zotova, E. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab. Invest. 2002, 82, 585-596.
138. Kalkanis, J.G.; Withworth, C.; Rybak, L.P. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004, 114, 538-542.
139. Paksoy, M.; Ayduran, E.; Sanli, A.; Eken, M.; Aydin, S.; Oktay, Z.A. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med. Oncol. 2011, 28, 615-621.
140. Campbell, K.C.; Meech, R.P.; Klemens, J.J.; Gerberi, M.T.; Dyrstad, S.S.; Larsen, D.L.; Mitchell, D.L.; El-Azizi, M.; Verhulst, S.J.; Hughes, L.F. Prevention of noise-and drug-induced hearing loss with D-methionine. Hear. Res. 2007, 226, 92-103.
141. Rybak, L.P.; Whitworth, C.; Somani, S. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 1999, 109, 1740-1744.
142. Ford, M.S.; Nie, Z.; Whitworth, C.; Rybak, L.P.; Ramkumar, V. Upregulation of adenosine receptors in the cochlea by cisplatin. Hear. Res. 1997, 111, 143-152.
143. Ford, M.S.; Maggirwar, S.B.; Rybak, L.P.; Whitworth, C.; Ramkumar, V. Expression and function of adenosine receptors in the chinchilla cochlea. Hear. Res. 1997, 105, 130-140.
144. Van der Hoop, R.G.; Vecht, C.J.; van der Burg, M.E. Prevention of cisplatin neurotoxicity wiht an ACTH (4-9) analogue in patients with ovarian cancer. N. Engl. J. Med. 1990, 332, 89-94.
145. Hamers, F.P.; Wijbenga, J.; Wolters, F.L. Cisplatin ototoxicity involves organ of Corti, stria vascularis and spiral ganglion: Modulation by alphaMSH and ORG 2766. Audiol. Neurootol. 2003, 8, 305-315.
146. Bowers, W.J.; Chen, X.; Guo, H.; Frisina, D.R.; Federoff, H.J.; Frisina, R.D. Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuro ototoxicity in the cochlea. Mol. Ther. 2002, 6, 12-18.
147. Huang, X.; Whitworth, C.A.; Rybak, L.P. Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats. Otol. Neurotol. 2007, 28, 828-833.
148. Zhang, M.; Liu, W.; Ding, D.; Salvi, R. Pifithrin-Alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neurorscience 2003, 120, 191-205.
149. Chan, D.K.; Lieberman, D.M.; Musatov, S. Protection against cisplatin-induced ototoxicity by adeno-associated virus-mediated delivery of the X-linkedd inhibitor of apoptosis protein is not dependent on caspase inhibition. Otol. Neurotol. 2007, 28, 417-425.
150. Light, J.P.; Silverstein, H. Transtympanic perfusion: Indications and limitations. Curr. Opin. Otolaryngol. Head Neck Surg. 2004, 12, 378-383.
151. Janning, M.H.; Whitworth, C.A.; Rybak, L.P. Experimental model of cisplatin ototoxicity in chinchillas. Otolaryngol. Head Neck Surg. 1998, 119, 574-580.
152. He, J.; Yin, S.; Wang, J.; Ding, D.; Jiang, H. Effectiveness of different approaches for establishing cisplatin-induced cochlear lesions in mice. Acta Otolaryngol. 2009, 129, 1359-1367.
153. Xia, L.; Chen, Z.; Yin, S. Ototoxicity of cisplatin administered to guinea pigs via the round window membrane. J. Toxicol. Sci. 2012, 37, 823-830.
154. Hoffmann, K.K.; Silverstein, H. Inner ear perfusion: Indications and applications. Curr. Opin. Otolaryngol. Head Neck Surg. 2003, 11, 334-339.
155. Plontke, S.K; Biegner, T.; Kammerer, B.; Delabar, U.; Salt, A.N. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol. Neurotol. 2008, 29, 401-406.
156. Goycoolea, M.V.; Lundman, L. Round window membrane. Structure, function and permeability: A review. Microsc. Res. Tech. 1997, 36, 201-211.
157. Laurell, G.; Teixeira, M.; Sterkers, O. Local administration of antioxidants to the inner ear. Kinetics and distribution (1). Hear. Res. 2002, 173, 198-209.
158. Grindal, T.C.; Sampson, E.M.; Antonelli, P.J. AM-111 prevents hearing loss from semicircular canal injury in otitis media. Laryngoscope 2010, 120, 178-182.
159. Horie, R.T.; Sakamoto, T.; Nakagawa, T.; Tabata, Y.; Okamura, N.; Tomiyama, N.; Tachibana, M.; Ito, J. Sustained delivery of lidocaine into the cochlea using Poly lactic/glycolic acid microparticles. Laryngoscope 2010, 120, 377-383.
160. King, E.B.; Salt, A.N.; Eastwood, H.T.; O'Leary, S.J. Direct entry of gadolinium into thevestibule following intratympanic applications in Guinea pigs and the influence of cochlear implantation. J. Assoc. Res. Otolaryngol. 2011, 12, 741-751.
161. Zou, J.; Pyykkö, I. Enhanced oval window and blocked round window passages for middle-inner ear transportation of gadolinium in guinea pigs with a perforated round window membrane. Eur. Arch. Otorhinolaryngol. 2015, 272, 303-309.
162. King, E.B.; Salt, A.N.; Kel, G.E.; Eastwood, H.T.; O'Leary, S.J. Gentamicin administration on the stapes footplate causes greater hearing loss and vestibulotoxicity than round window administration in guinea pigs. Hear. Res. 2013, 304, 159-166.
163. Schuknecht, H.F. Ablation therapy for the relief of Ménière's disease. Laryngoscope 1956, 66, 859-870.
164. Parham, K. Can intratympanic dexamethasone protect against cisplatin ototoxicity in mice with age-related hearing loss?. Otolaryngol. Head Neck Surg. 2011, 145, 635-640.
165. Topdag, M.; Iseri, M.; Gelenli, E.; Yardimoglu, M.; Yazir, Y.; Ulubil, S.A.; Topdag, D.O.; Ustundag, E. Effect of intratympanic dexamethasone, memantine and piracetam on cellular apoptosis due to cisplatin ototoxicity. J. Laryngol. Otol. 2012, 126, 1091-1096.
166. Murphy, D.; Daniel, S.J. Intratympanic dexamethasone to prevent cisplatin ototoxicity: A guinea pig model. Otolaryngol. Head Neck Surg. 2011, 145, 452-457.
167. Shafik, A.G.; Elkabarity, R.H.; Thabet, M.T; Soliman, N.B.; Kalleny, N.K. Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs. Auris. Nasus. Larynx 2013, 40, 51-60.
168. Hughes, A.L.; Hussain, N.; Pafford, R.; Parham, K. Dexamethasone otoprotection in a multidose cisplatin ototoxicity mouse model. Otolaryngol. Head Neck Surg. 2014, 150, 115-120.
169. Roehm, P.; Hoffer, M.; Balaban, C.D. Gentamicin uptake in the chinchilla inner ear. Hear. Res. 2007, 230, 43-52.
170. Blakley, B.W. Update on intratympanic gentamicin for Meniere's disease. Laryngoscope 2000, 110(2 Pt 1), 236-240.
171. Saliba, I.; el Fata, F.; Ouelette, V.; Robitaille, Y. Are intratympanic injections of N-acetylcysteine and methylprednisolone protective against Cisplatin-induced ototoxicity?. J. Otolaryngol. Head Neck Surg. 2010, 39, 236-243.
172. Van As, J.W.; van den Berg, H.; van Dalen, E.C. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst. Rev. 2014, 7, CD009219.
173. Riga, M.G.; Chelis, L.; Kakolyris, S.; Papadopoulos, S.; Stathakidou, S.; Chamalidou, E.; Xenidis, N.; Amarantidis, K.; Dimopoulos, P.; Danielides, V. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: A feasible method with promising efficacy. Am. J. Clin. Oncol. 2013, 36, 1-6.
174. Gurney, J.G.; Bass, J.K.; Onar-Thomas, A.; Huang, J.; Chintagumpala, M.; Bouffet, E.; Hassall, T.; Gururangan, S.; Heath, J.A.; Kellie, S.; et al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro. Oncol. 2014, 16, 848-855.